OR WAIT null SECS
December 13, 2022
The approval is based on results from the pivotal EFFISAYIL 1 Phase II clinical trial.
mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.
December 12, 2022
Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.
PictorLabs, a digital pathology company developing an AI-powered virtual staining platform, formally announced its launch at the start of December.
The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.
The R&D analytical solutions will consist of analytical lab services that use USP’s in-house scientific expertise and state-of-the-art facilities at the USP Advanced Manufacturing Technology Lab in Richmond and the USP headquarters facility in Rockville, Md.
December 07, 2022
Ferring Pharmaceuticals’ Rebyota was approved for the prevention of recurrence of Clostridioides difficile infection.
The partnership will see the pharma giants partner with researchers from A*STAR and various Singapore universities.
December 05, 2022
In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.
December 02, 2022
Pharmaceutical Technology Europe got the scoop on Agilent's new Dissolution Testing Centre of Excellence in Craven Arms, UK.